Good news continues to stack up for Neurocrine Biosciences (NBIX), with the company's partner AbbVie (ABBV)
announcing on Wednesday that its first of two Phase III studies of
elagolix in uterine fibroids met all of its efficacy endpoints. This
continues a pretty good run of success with Neurocrine's late-stage
pipeline and brings another potential multi-billion-dollar drug that
much closer to approval and commercialization.
While
there are still more steps to go through with elagolix in uterine
fibroids (namely, full results from both studies, including safety
data), the similarities between the Phase III and Phase II results thus
far would suggest that there's not much reason for worry (then again
"surprises" are by their nature not expected…). Approval of elagolix in
2019 or 2020 would bring another important revenue generator to market
for Neurocrine and this incremental step does modestly boost my fair
value.
Continue here:
Another Phase III Win For Neurocrine Biosciences
No comments:
Post a Comment